Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | May 10, 2018 at 10:40 AM EDT

Big Biotechs Scare Off Short Sellers

The April 30 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | May 10, 2018 at 10:20 AM EDT

Short Sellers Run for Cover From Major Pharma

The April 30 short interest data have been compared with the previous figures, and short interest in most of these…

Lee Jackson | May 10, 2018 at 10:05 AM EDT

4 Specialty Pharma Stocks That Deutsche Bank Likes for the Rest of 2018

There is deep value for long-term investors in these specialty pharmaceutical companies, and the ability to buy in to some…

Chris Lange | May 8, 2018 at 9:05 AM EDT

What Will Become of Valeant Pharmaceuticals?

Valeant Pharmaceuticals released its most recent quarterly report and announced a name change before the markets opened on Tuesday.

Chris Lange | May 7, 2018 at 1:40 PM EDT

Are Athenahealth Shareholders Getting Enough in This Go-Private Offer?

Athenahealth shares are jumping on Monday after it was announced that Elliot Management wants to take the company private.

Chris Lange | May 5, 2018 at 8:40 AM EDT

The Top Biopharma Catalysts Coming in May

Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates…

Chris Lange | May 4, 2018 at 11:10 AM EDT

Portola Pharmaceuticals Wins Big With FDA Approval

Portola Pharmaceuticals saw its shares soar on Friday after the firm announced that it had received an approval from the…

Chris Lange | May 3, 2018 at 1:40 PM EDT

Why Achaogen Shares Are Getting Crushed

As we have said before, the FDA has the potential to make or break biopharma companies, and in this case…

Chris Lange | May 3, 2018 at 8:35 AM EDT

Is This the Turnaround Teva Has Been Waiting For?

Teva Pharmaceutical Industries released its most recent quarterly report before the markets opened on Thursday.

Chris Lange | May 2, 2018 at 1:46 PM EDT

Why InVivo Therapeutics Shares Are Skyrocketing

InVivo Therapeutics shares absolutely skyrocketed on Wednesday after the firm provided an update on results from the company’s single-arm INSPIRE…

Jon C. Ogg | May 2, 2018 at 12:05 PM EDT

Analysts Show More Caution Toward Gilead’s Mystical Recovery

Gilead Science was supposed to be coming back as a company on the heels of its first major acquisition in…

Chris Lange | May 2, 2018 at 10:40 AM EDT

Can Esperion Therapeutics Go the Distance After This Report?

Esperion Therapeutics released its first-quarter financial results and a business update before the markets opened on Wednesday.

Chris Lange | May 2, 2018 at 8:45 AM EDT

Why Gilead Sciences Whiffed in Q1

Gilead Sciences released disappointing first-quarter financial results late Tuesday and shares tumbled early Wednesday.

Douglas A. McIntyre | May 2, 2018 at 7:00 AM EDT

Many Face Difficult Summer as Mosquitoes and Ticks Surge

In some parts of the country, infestations of dangerous mosquitoes, ticks and fleas will make the outdoor activity risky, according…

Chris Lange | May 1, 2018 at 12:59 PM EDT

Why Karyopharm Is on the Move

Karyopharm Therapeutics saw its shares make a handy gain on Tuesday after the firm announced positive top-line results from the…

1 … 133 134 135 136 137 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Big Biotechs Scare Off Short Sellers

Short Sellers Run for Cover From Major Pharma

4 Specialty Pharma Stocks That Deutsche Bank Likes for the Rest of 2018

What Will Become of Valeant Pharmaceuticals?

Are Athenahealth Shareholders Getting Enough in This Go-Private Offer?

The Top Biopharma Catalysts Coming in May

Portola Pharmaceuticals Wins Big With FDA Approval

Why Achaogen Shares Are Getting Crushed

Is This the Turnaround Teva Has Been Waiting For?

Why InVivo Therapeutics Shares Are Skyrocketing

Analysts Show More Caution Toward Gilead’s Mystical Recovery

Can Esperion Therapeutics Go the Distance After This Report?

Why Gilead Sciences Whiffed in Q1

Many Face Difficult Summer as Mosquitoes and Ticks Surge

Why Karyopharm Is on the Move

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Big Biotechs Scare Off Short Sellers

Short Sellers Run for Cover From Major Pharma

4 Specialty Pharma Stocks That Deutsche Bank Likes for the Rest of 2018

What Will Become of Valeant Pharmaceuticals?

Are Athenahealth Shareholders Getting Enough in This Go-Private Offer?

The Top Biopharma Catalysts Coming in May

Portola Pharmaceuticals Wins Big With FDA Approval

Why Achaogen Shares Are Getting Crushed

Is This the Turnaround Teva Has Been Waiting For?

Why InVivo Therapeutics Shares Are Skyrocketing

Analysts Show More Caution Toward Gilead’s Mystical Recovery

Can Esperion Therapeutics Go the Distance After This Report?

Why Gilead Sciences Whiffed in Q1

Many Face Difficult Summer as Mosquitoes and Ticks Surge

Why Karyopharm Is on the Move

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how